Biotech Investment
Funding rounds, deals, M&A and the money moving the sector.
Latest Biotech Investment news
Arch Biopartners Faces Downside Pressure Following 4.30% Decline: Clinical Trial Execution, Funding Runway, and Biotech Sentiment in Focus
Read at kalkine.ca →Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
Read at Fierce Biotech →CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
Read at Fierce Biotech →SBIO ETF Rallies on Clinical Trial Wins & M&A Demand
Read at ETF Trends →Sarat Ventures Targets USD 100M to Invest in 15 to 20 Biotech Companies
Read at waya.media →Sudarshan Pharma acquires 9.50% stake in US firm MedTherapy Biotech
Read at scanx.trade →From the knowledge base
Trialynx Wins DPHARM Idol Disrupt 2026
Trialynx takes home the DPHARM Idol Disrupt award from the 2026 DPHARM conference.
Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts
Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.
Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry
New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, mirroring an earlier clinical success from Otsuka’s Voyxact and heating up competition in a rapidly evolving market race.
AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer
After a 2024 rebuff, AstraZeneca and Daiichi Sankyo’s star antibody drug conjugate Enhertu has been deemed cost effective for NHS use in HER2-low advanced breast cancer by England and Wales' drug value assessor.
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.